natgillin/translations-raw huggingface dataset:
When followed by a 2.0 microgram/kg/min continuous infusion, this regimen produces a > 80 % inhibition of ADP-induced ex vivo platelet aggregation, at physiologic calcium concentrations, in more than 80 % of patients. 
Če temu sledi trajna infuzija 2,0 mikrograma/kg/min, lahko taka shema pri več kot 80 % bolnikov povzroči > 80 % zaviranje z ADP-jem inducirane agregacije trombocitov ex vivo pri fiziološki koncentraciji kalcija.
Eptifibatide, a synthetic cyclic heptapeptide containing six amino acids, including one cysteine amide and one mercaptopropionyl (desamino cysteinyl) residue, is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics. 
Eptifibatid, sintetični ciklični heptapeptid s šestimi aminokislinami, vključno z eno cisteinamidno in eno merkaptopropionilno (dezaminocisteinilno) skupino, je zaviralec agregacije trombocitov in sodi v skupino RGD (arginin-glicin-aspartat)-mimetikov.
2 mg/ml : 3.45 mg/ml (0.150 mmol/ml) sodium For the full list of excipients, see section 6.1. 
2 mg/ml: 3,45 mg/ml (0,150 mmol/ml) natrija Za celoten seznam pomožnih snovi glejte poglavje 6.1.
− During use of Eptifibatide Accord, you will be checked carefully for any signs of unusual or unexpected bleeding. 
− Med uporabo zdravila Eptifibatide Accord vas bodo skrbno spremljali, da ugotovijo morebitne znake nenavadne ali nepričakovane krvavitve.
Other medicines and Eptifibatide Accord 
Druga zdravila in zdravilo Eptifibatide Accord
There was no excessive bleeding in any of these patients, although one patient undergoing CABG surgery was reported as having had a moderate bleed. 
Noben od teh bolnikov ni imel čezmerne krvavitve, le pri enem pa so poročali o zmerni krvavitvi med koronarno premostitveno operacijo.
Contents of the pack and other information What Eptifibatide Accord contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Eptifibatide Accord
Thrombocytopenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals. 
Trombocitopenijo, ki se pojavi po prvi izpostavljenosti zaviralcu GPIIb/IIIa, se lahko pojasni s tem, da so protitelesa pri nekaterih zdravih osebah naravno prisotna.
− if you have had a brain tumour or a condition that affects the blood vessels around the brain. 
− če ste imeli možganski tumor ali katero od bolezni, ki vplivajo na možganske krvne žile;
Clinical Trials 
KLINIČNI PODATKI
Intravenous use Read the package leaflet before use. 
intravenska uporaba Pred uporabo preberite navodilo za uporabo!
Eptifibatide inhibits platelet aggregation in a dose- and concentration-dependent manner as demonstrated by ex vivo platelet aggregation using adenosine diphosphate (ADP) and other agonists to induce platelet aggregation. 
Eptifibatid zavira agregacijo trombocitov odvisno od odmerka in koncentracije, kot je pokazala agregacija trombocitov ex vivo z uporabo adenozindifosfata (ADP) in drugih agonistov za indukcijo agregacije trombocitov.
In PURSUIT, bleeding and non-bleeding events were collected from hospital discharge to the 30 day visit. 
V študiji PURSUIT so od odpusta iz bolnišnice do pregleda 30. dan beležili krvavitvene in nekrvavitvene dogodke.
Keep the vial in the outer package in order to protect from light. 
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
However, in a population pharmacokinetic study there was no evidence of a pharmacokinetic interaction between eptifibatide and the following concomitant medicinal products: amlodipine, atenolol, atropine, captopril, cefazolin, diazepam, digoxin, diltiazem, diphenhydramine, enalapril, fentanyl, furosemide, heparin, lidocaine, lisinopril, metoprolol, midazolam, morphine, nitrates, nifedipine, and warfarin. 
V neki populacijski farmakokinetični študiji ni bilo znakov farmakokinetičnih interakcij, če so bolniki sočasno z eptifibatidom prejemali naslednja zdravila: amlodipin, atenolol, atropin, kaptopril, cefazolin, diazepam, digoksin, diltiazem, difenhidramin, enalapril, fentanil, furosemid, heparin, lidokain, lizinopril, metoprolol, midazolam, morfin, nitrate, nifedipin in varfarin.
Stop heparin administration if the ACT exceeds 300 seconds; do not administer until the ACT falls below 300 seconds. 
Če AČS preseže 300 sekund, morate prenehati z dajanjem heparina in ga ne smete ponovno uporabiti, dokler AČS ne pade pod 300 sekund.
MI could also be reported following CEC adjudication of an investigator report. 
Miokardni infarkt je bil lahko prijavljen tudi po presoji KKP, na podlagi njihove ocene poročila raziskovalcev.
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (Dphenylalanyl-L-prolyl-L-arginine chloromethyl ketone anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50 % inhibitory concentration) of approximately 550 ng/ml and an IC80 (80 % inhibitory concentration) of approximately 1,100 ng/ml. 
Merjenje z ADP-jem inducirane agregacije trombocitov ex vivo pri fiziološki koncentraciji kalcija (antikoagulant D-fenilalanil-L-prolil-L-arginin klorometilketon ) pri bolnikih z nestabilno angino pektoris in miokardnim infarktom brez zobca Q v EKG je pokazalo od koncentracije odvisno zaviranje, z IK50 vrednostjo (50 % inhibicijsko koncentracijo) približno 550 nanogramov/ml in IK80 (80 % inhibicijsko koncentracijo) približno 1.100 nanogramov/ml.
This study was a 726-center, 27-country, double-blind, randomised, placebo-controlled study in 10,948 patients presenting with UA or NQMI. 
Potekala je v 726 centrih v 27 državah in je bila dvojno slepa, randomizirana in s placebom kontrolirana študija pri 10.948 bolnikih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v EKG.
After removal of the introducer sheath, careful haemostasis must be ensured under close observation. 
Po odstranitvi uvajalnega vodila morate zagotoviti skrbno hemostazo z natančnim spremljanjem bolnika.
Eptifibatide and thrombolytic agents 
Eptifibatid in trombolitična zdravila
If the patient requires emergency or urgent cardiac surgery during the course of eptifibatide therapy, terminate the infusion immediately. 
Če bolnik med zdravljenjem z eptifibatidom potrebuje nujno ali urgentno operacijo na srcu, nemudoma prekinite infuzijo.
The first bolus and the infusion were started simultaneously, immediately before the PCI procedure and were followed by a second bolus 10 minutes after the first. 
Prvi bolusni odmerek in infuzijo so bolniki prejeli hkrati, tik pred perkutanim koronarnim posegom, drugi bolusni odmerek pa 10 minut po prvem.
Your doctor will weigh up the benefit to you against the risk to your baby of using Eptifibatide Accord while you are pregnant. 
Zdravnik bo pretehtal koristi, ki jih uporaba zdravila Eptifibatide Accord med nosečnostjo pomeni za vas, v primerjavi s tveganjem, ki ga pomeni za otroka.
Table 1: Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population) 
Tabela 1: Incidenca smrti oz. MI po oceni KKP (populacija “zdravljena v skladu z razporeditvijo v skupine”)
The dose given is based on your weight. 
Odmerek, ki ga boste prejeli, se določi glede na telesno maso.
Patients most likely to benefit from eptifibatide treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina. 
Bolniki, pri katerih je verjetnost, da jim bo zdravljenje z eptifibatidom koristilo, največja, so predvsem tisti z velikim tveganjem za razvoj miokardnega infarkta v prvih 3 do 4 dneh po pojavu akutnih simptomov angine pektoris.
− if you have had a stroke within the past 30 days or any haemorrhagic stroke (also, be sure your doctor knows if you ever had a stroke). 
− če ste imeli v zadnjih 30 dneh možgansko kap ali če ste kdaj v preteklosti imeli hemoragično možgansko kap (svojemu zdravniku morate tudi povedati, če ste kdaj doživeli možgansko kap);
Concurrent administration of heparin is recommended unless this is contraindicated for reasons such as a history of thrombocytopenia associated with use of heparin (see ‘Heparin administration', section 4.4). 
Sočasna uporaba heparina je priporočljiva, če zanj ni kontraindikacij, npr. anamneze o trombocitopeniji, povezani z uporabo heparina, (glejte "Uporaba heparina", poglavje 4.4).
Haemoglobin, haematocrit, and platelet count are to be monitored as well within 6 hours after start of therapy and at least once daily thereafter while on therapy (or more often if there is evidence of a marked decrease). 
Hemoglobin, hematokrit in število trombocitov morate spremljati tudi v prvih 6 urah po začetku zdravljenja, nato pa vsaj enkrat na dan ves čas zdravljenja ali pa še pogosteje, če pride do znakov občutnega zmanjšanja.
In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of eptifibatide -treated patients vs. 4.6 % of placebo-treated patients. 
V podskupini bolnikov, ki so jim naredili perkutano koronarno intervencijo, so bile večje krvavitve pogoste: pojavile so se pri 9,7 % zdravljenih z eptifibatidom in 4,6 % prejemnikov placeba.
Before using, the vial contents should be inspected. 
Pred uporabo morate pregledati vsebino viale.
What you need to know before you are given Eptifibatide Accord Do not use Eptifibatide Accord: 
Kaj morate vedeti, preden boste dobili zdravilo Eptifibatide Accord Zdravila Eptifibatide Accord ne smete dobiti:
− if you have recently had bleeding from your stomach, intestines, bladder or other organs, for example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
− če ste pred nedavnim krvaveli iz želodca, črevesja, sečnega mehurja ali drugih organov, npr. če ste imeli v preteklih 30 dneh kri v blatu ali seču (razen v primeru menstruacije);
How to store Eptifibatide Accord Contents of the pack and other information 
Shranjevanje zdravila Eptifibatide Accord Vsebina pakiranja in dodatne informacije
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. 
Zdravilo Eptifibatide Accord je namenjeno uporabi z acetilsalicilno kislino in nefrakcioniranim heparinom.
Early routine eptifibatide in this high-risk NSTE-ACS optimally-treated population who were managed with an invasive strategy did not result in a statistically significant reduction in the composite primary endpoint of rate of death, MI, RI-UR, and TBO within 96 hours compared with a regimen of delayed provisional eptifibatide (9.3 % in early eptifibatide patients vs. 10.0 % in patients assigned to delayed provisional eptifibatide; odds ratio=0.920; 95 % CI=0.802-1.055; p=0.234). 
Zgodnja rutinska uporaba eptifibatida v tej optimalno zdravljeni populaciji z velikim tveganjem akutnega koronarnega sindroma brez elevacije ST ni statistično značilno zmanjšala sestavljene primarne končne točke (deleža smrti, MI, ponovne ishemije s potrebo po nujni revaskularizaciji (RIUR) in reševanja tromboze (TBO)) v 96 urah v primerjavi s shemo odložene pomožne uporabe eptifibatida (9,3 % med bolniki z zgodnjo uporabo eptifibatida v primerjavi z 10,0 % med bolniki z odloženo pomožno uporabo; razmerje obetov = 0,920, 95 % IZ = 0,802-1,055, p = 0,234).
The most common bleeding complications were associated with cardiac invasive procedures (coronary artery bypass grafting (CABG)-related or at femoral artery access site). 
Najpogostejši krvavitveni zapleti so bili povezani z invazivnimi postopki na srcu (obvodom koronarne arterije ali na dostopu v stegensko arterijo).
Major bleeding was defined in the PURSUIT trial as either an intracranial haemorrhage or a decrease in haemoglobin concentrations of more than 5 g/dl. 
Kot večje krvavitve so bile v študiji PURSUIT opredeljene intrakranialna krvavitev ali zmanjšanje koncentracije hemoglobina za več kot 5 g/dl.
Toxicology studies conducted with eptifibatide include single and repeated dose studies in the rat, rabbit and monkey, reproduction studies in the rat and rabbit, in vitro and in vivo genetic toxicity studies, and irritation, hypersensitivity and antigenicity studies. 
Med toksikološkimi študijami z eptifibatidom je potekalo tudi preučevanje uporabe enkratnih in večkratnih odmerkov pri podganah, kuncih in opicah, preučevanje reprodukcije pri podganah in kuncih, preučevanje genetične toksičnosti in vitro ter in vivo in ugotavljanje dražilnih učinkov, preobčutljivosti in antigenosti zdravila.
If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period. 
Če dojite, morate v času zdravljenja z dojenjem prenehati.
− The active substance is eptifibatide. 
− Zdravilna učinkovina je eptifibatid.
Pharmacotherapeutic group: Antithrombotic agent (platelet aggregation inhibitors excl. heparin), ATC code: B01AC16 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: Antitrombotična zdravila (zaviralci agregacije trombocitov z izjemo heparina), ATC oznaka: B01AC16 Mehanizem delovanja
For a particular adverse reaction, if data was available from both PURSUIT and ESPRIT, then the highest reported incidence was used to assign adverse reaction frequency. 
V primeru, da so bili podatki na voljo tako iz študije PURSUIT kot ESPRIT, je bila za razvrstitev pogostnosti neželenega učinka za vsak posamezen neželen učinek uporabljena največja zabeležena incidenca.
In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg. 
V isti populaciji je razpolovni čas eliminacije zdravila iz plazme približno 2,5 ur, plazemski očistek od 55 do 80 ml/kg/h,
At the highest infusion rates (1.3 microgram/kg/min and 2.0 microgram/kg/min) studied, eptifibatide was associated with an increased incidence of bleeding and transfusions compared to the incidence seen when streptokinase was given alone. 
Pri največjih proučenih hitrostih infundiranja (1,3 mikrograma/kg/min in 2,0 mikrograma/kg/min) je bila incidenca krvavitev in transfuzij pri sočasni uporabi eptifibatida večja kot pri uporabi same streptokinaze.
0.75 mg/ml : 1.72 mg/ml (0.075 mmol/ml) sodium For the full list of excipients, see section 6.1. 
0,75 mg/ml: 1,72 mg/ml (0,075 mmol/ml) natrija Za celoten seznam pomožnih snovi glejte poglavje 6.1.
If percutaneous coronary intervention (PCI) is performed during Eptifibatide Accord therapy, the intravenous solution may be continued for up to 96 hours. 
Če je bil med zdravljenjem z zdravilom Eptifibatide Accord opravljen perkutani koronarni poseg (PCI), lahko intravenska infuzija traja do 96 ur.
ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with eptifibatide Therapy) was a double-blind, randomised, placebo-controlled trial (n= 2,064) for nonurgent PCI with intracoronary stenting. 
študija okrepljenega zaviranja trombocitnih receptorjev IIb/IIIa z eptifibatidom) je bila dvojno slepa, randomizirana in s placebom kontrolirana študija (n = 2.064) neurgentnega perkutanega koronarnega posega (PCI) z vstavitvijo intrakoronarne opornice.
Rash, application site disorders such as urticaria. 
Zelo redki težave na mestu aplikacije npr. urtikarija.
- if you have or have had severe kidney or liver problems. 
− če imate ali ste kdaj imeli hude težave z ledvicami ali jetri;
PURSUIT: This was a randomized, double-blind evaluation of the efficacy and safety of eptifibatide versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction. 
PURSUIT: To je bilo randomizirano, dvojno slepo ocenjevanje učinkovitosti in varnosti eptifibatida v primerjavi s placebom za zmanjšanje umrljivosti in (ponovnega) miokardnega infarkta pri bolnikih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v EKG.
While Thrombolysis in Myocardial Infarction TIMI bleeding criteria were used to categorize the incidence of major and minor bleeding in both the PURSUIT and the ESPRIT trials, PURSUIT data was collected within 30 days while ESPRIT data was limited to events within 48 hours or discharge, whichever came first. 
V obeh študijah, PURSUIT in ESPRIT, so bila za razvrstitev incidence večjih in manjših krvavitev uporabljena merila TIMI (Thrombolysis in Myocardial Infarction), toda v študiji PURSUIT so podatke zbirali 30 dni, v ESPRIT pa v 48 urah oz. do odpusta iz bolnišnice, kar od tega dvojega je bilo prej.
In an acute myocardial infarction study involving 181 patients, eptifibatide (in regimens up to a bolus injection of 180 microgram/kg, followed by an infusion up to 2 microgram/kg/min for up to 72 hours) was administered concomitantly with streptokinase (1.5 million units over 60 minutes). 
V raziskavi akutnega miokardnega infarkta, ki je zajela 181 bolnikov, so eptifibatid (v shemah z uporabo bolusne injekcije do 180 mikrogramov/kg, ki ji je sledila infuzija do 2 mikrograma/kg/min v trajanju do 72 ur) uporabili sočasno s streptokinazo (1,5 milijona enot v 60 minutah).
Similar results were also obtained for the 2 secondary endpoints assessed at 30 days: a triple composite of death, MI and UTVR, and the more robust combination of death and MI. 
Podobne rezultate so dobili tudi za dva sekundarna končna cilja, ocenjena po 30 dneh: trikratni sestavljeni rezultat, opredeljen kot seštevek podatkov za smrt, miokardni infarkt in urgentno revaskularizacijo prizadete žile ter bolj groba ocena, opredeljena kot seštevek podatkov za smrt in miokardni infarkt.
− minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding with surgical procedures). 
- manjše ali večje krvavitve (npr. kri v seču, kri v blatu, kri v izbruhani vsebini ali krvavitve med kirurškimi posegi);
There is limited therapeutic experience with eptifibatide in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG). 
Terapevtske izkušnje z uporabo eptifibatida so skope pri bolnikih, pri katerih je praviloma indicirano trombolitično zdravljenje (npr. tistih z akutnim transmuralnim miokardnim infarktom z novimi patološkimi zobci Q, zvišanjem spojnice ST ali levokračnim blokom v EKG).
At the recommended therapeutic dose, as administered in the PURSUIT trial involving nearly 11,000 patients, bleeding was the most common complication encountered during eptifibatide therapy. 
PURSUIT, ki je zajelo skoraj 11.000 bolnikov, so bile krvavitve med zdravljenjem z eptifibatidom najpogostejši zaplet.
The incidence of severe or life threatening bleeding events with eptifibatide was 1.9 % compared to 1.1 % with placebo. 
Incidenca hudih ali smrtno nevarnih krvavitev je bila med uporabo eptifibatida 1,9 % in med uporabo placeba 1,1 %.
Heparin administration is recommended unless a contraindication (such as a history of thrombocytopenia associated with use of heparin) is present. 
Uporaba heparina je priporočljiva le, če zanj ni kontraindikacij (npr. trombocitopenija v anamnezi v povezavi z uporabo heparina).
Arterial sheaths may be removed when coagulation has returned to normal (e.g. when activated clotting time (ACT) is less than 180 seconds (usually 2-6 hours after discontinuation of heparin). 
ko je aktivirani čas strjevanja (AČS) manjši od 180 sekund; ponavadi 2 do 6 ur po ukinitvi heparina).
Eptifibatide Accord is given into the vein by direct injection followed by an infusion (drip solution). 
Zdravilo Eptifibatide Accord se daje z injekcijo v veno, temu pa sledi (kapalna) infuzija.
Experience in patients with hepatic impairment is very limited. 
Izkušnje pri bolnikih z jetrno okvaro so zelo skope.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled. 
Pri bolnikih z zmerno do hudo ledvično insuficienco (kreatininski očistek < 50 ml/min) je očistek eptifibatida za približno 50 % manjši, plazemske koncentracije v stanju dinamičnega ravnovesja pa so približno podvojene.
In the eptifibatide arm of the trial, virtually all patients received aspirin (99.7 %), and 98.1 % received a thienopyridine, (clopidogrel in 95.4 % and ticlopidine in 2.7 %). 
V kraku študije z eptifibatidom so praktično vsi bolniki prejeli tudi acetilsalicilno kislino (99,7 %), 98,1 % pa jih je prejelo zdravilo iz skupine tienopiridinov (klopidogrel 95,4 % in tiklopidin 2,7 %).
Eptifibatide Accord 2 mg/ml solution for injection contains 57.96 mg (2.52 mmol) of sodium per maximum daily dose. 
Eptifibatide Accord 2 mg/ml raztopina za injiciranje vsebuje 57,96 mg /2,52 mmol) natrija na največji dnevni odmerek.
If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse immediately. 
Če se pojavi huda alergijska reakcija ali koprivnica, to nemudoma povejte zdravniku, bolnišničnemu farmacevtu ali medicinski sestri.
The rate of infusion was 2.0 microgram/kg/min for patients with serum creatinine ≤ 175 micromols/l or 1.0 microgram/kg/min for serum creatinine > 175 up to 350 micromols/l. 
Hitrost infuzije pri bolnikih s serumskim kreatininom ≤ 175 mikromolov/l je bila 2,0 mikrograma/kg/min, pri tistih s serumskim kreatininom > 175 do 350 mikromolov/l pa 1,0 mikrogram/kg/min.
The experience in humans with overdose of eptifibatide is extremely limited. 
Izkušnje s prevelikim odmerjanjem eptifibatida pri človeku so izredno skope.
Patients could be medically managed, proceed to coronary artery bypass graft (CABG), or undergo percutaneous coronary intervention (PCI). 
Bolniki so bili lahko vodeni konzervativno, zdravljeni z obvodno operacijo koronarnih arterij (CABG) ali s perkutanim koronarnim posegom.
− serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs) 
- hude krvavitve (na primer, krvavitve v trebušni votlini, možganih ali v pljuča);
The placebo arm was comparable (aspirin 99.7 %, clopidogrel 95.9 %, ticlopidin 2.6 %). 
Za placebo krak študije je veljalo podobno: acetilsalicilna kislina (99,7 %, klopidogrel 95,9 % in tiklopidin 2,6 %).
Patients were randomised to either placebo, eptifibatide 180 microgram/kg bolus followed by a 2.0 microgram/kg/min infusion (180/2.0), or eptifibatide 180 microgram/kg bolus followed by a 1.3 microgram/kg/min infusion (180/1.3). 
Bolniki so bili naključno razvrščeni bodisi v skupino za zdravljenje s placebom, skupino za zdravljenje z bolusom eptifibatida 180 mikrogramov/kg in potem z infuzijo 2,0 mikrograma/kg/min (180/2,0), ali pa v skupino za zdravljenje z bolusom eptifibatida 180 mikrogramov/kg in potem z infuzijo 1,3 mikrograma/kg/min (180/1,3).
These may affect up to 1 in 100 people - reduction in the number of platelets (blood cells necessary for blood clotting). 
Pojavijo se pri 1 do 10 bolnikih od 1.000 bolnikov - zmanjšanje števila trombocitov (krvnih celic, ki so potrebne za strjevanje krvi); - zmanjšana prekrvavitev možganov.
Eptifibatide Accord 0.75 mg/ml solution for infusion contains 77.4 mg (3.37 mmol) of sodium per maximum daily dose. 
Natrij Eptifibatide Accord 0,75 mg/ml raztopina za infundiranje vsebuje 77,4 mg (3,37 mmol) natrija na največji dnevni odmerek.
In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min. 
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek od 30 do 50 ml/min) je bila 100 % inhibicija dosežena 24 ur po uporabi 2 mikrograma/kg/min.
Women, the elderly, patients with low body weight or with moderate renal impairment (creatinine clearance > 30 - < 50 ml/min) may have an increased risk of bleeding. 
Nevarnost za krvavitve je lahko večja pri ženskah, starejših bolnikih, bolnikih z majhno telesno maso ali z zmerno okvaro ledvic (kreatininski očistek ≥ 30 - < 50 ml/min).
For a 2.0 microgram/kg/min infusion, mean steady-state plasma eptifibatide concentrations range from 1.5 to 2.2 microgram/ml in patients with coronary artery disease. 
Pri infundiranju 2,0 mikrograma/kg/min je srednja ravnovesna koncentracija eptifibatida v plazmi pri bolnikih z boleznijo koronarnih arterij od 1,5 do 2,2 mikrograma/ml.